[vc_row][vc_column][vc_column_text]

The present invention belongs to the field of nucleic acid constructs, viral vectors and viral particles for use in the treatment and/or prevention of disease associated with a loss of solute carrier family 6 member 1 (SLC6A1) function such as myoclonic atonic epilepsy (MAE), MAE-like and other epilepsy indications such as Lennox-Gastaut Syndrome as well as autism spectrum disorder and schizophrenia

[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][contact-form-7 id="70"][vc_line_chart values="%5B%7B%22title%22%3A%22One%22%2C%22y_values%22%3A%2210%3B%2015%3B%2020%3B%2025%3B%2027%3B%2025%3B%2023%3B%2025%22%2C%22color%22%3A%22blue%22%7D%2C%7B%22title%22%3A%22Two%22%2C%22y_values%22%3A%2225%3B%2018%3B%2016%3B%2017%3B%2020%3B%2025%3B%2030%3B%2035%22%2C%22color%22%3A%22pink%22%7D%5D" title="Trademark"][/vc_column][/vc_row][vc_row][vc_column][vc_empty_space][/vc_column][/vc_row][vc_row][vc_column][vc_hoverbox image="3934" primary_title="BACKGROUND OF THE INVENTION"]

Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

[/vc_hoverbox][/vc_column][/vc_row]